key: cord-0922742-ibph1u02 authors: Lynch, Kara L; Zhou, Shuxia; Kaul, Ravi; Walker, Roger; Wu, Alan H title: Evaluation of neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination using a multiplexed surrogate virus neutralization test date: 2022-01-09 journal: Clin Chem DOI: 10.1093/clinchem/hvab283 sha: 38f329266b805ba52eca063f48d137e2f97b93e4 doc_id: 922742 cord_uid: ibph1u02 BACKGROUND: The SARS-CoV-2 virus has mutated and evolved since the inception of the COVID-19 pandemic bringing into question the future effectiveness of current vaccines and antibody therapeutics. With evolution of the virus updated methods for the evaluation of the immune response in infected and vaccinated individuals are required to determine the durability of the immune response to SARS-CoV-2 variants. METHODS: We developed a multiplexed surrogate virus neutralization test (plex-sVNT) that simultaneously measures the ability of antibodies in serum to inhibit binding between angiotensin converting enzyme-2 (ACE2) and 7 SARS-CoV-2 trimeric spike protein variants, including wild type, B.1.1.7(α), B.1.351(β), P.1(γ), B.1.617.2(δ), B.1.617.1(κ), and B.1.429(ε). The assay was validated against a plaque reduction neutralization test (PRNT). We evaluated 170 samples from 97 COVID-19 patients and 281 samples from 188 individuals that received the Pfizer-BioNTech or Moderna mRNA vaccines. RESULTS: The plex-sVNT demonstrated >96% concordance with PRNT. Antibody neutralization activity was significantly reduced for all SARS-CoV-2 variants compared to wild type in both the infected and vaccinated cohorts. There was a decline in overall antibody neutralization activity, within both cohorts, out to 5 months post infection or vaccination, with the rate of decline being more significant for the vaccinated. CONCLUSIONS: The plex-sVNT provides a correlative measure to PRNT and a convenient approach for evaluating antibody neutralization against SARS-CoV-2 variants. Neutralization of SARS-CoV-2 variants is reduced compared to wild type and declines over the ensuing months after exposure or vaccination within each cohort, however it is still unknown what degree of neutralizing capacity is protective. individuals for all major variants of concern using the same analytical method for comparison. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 two or more samples were collected from a subject, they were separated by at least 7 days. The 94 median number of specimens per subject was 1 for the Pfizer-BioNTech and 2 for Moderna. 95 Demographic data and dates of vaccination were collected following informed consent. All samples were maintained at -20  C for the duration of the study. After thawing at 97 room temperature, samples were briefly vortexed before testing in singlicate. Estonia. Recombinant trimeric spike protein for the WA1 strain was not commercially available. Besides variant specific mutations, each trimeric protein contains aa 14-1211, plus two extra 105 amino acids (AS) in the N-terminus, trimerization domain and His-6 tag at its C-terminus. Also 106 added is a GS linker between the protein and trimerization domain as well as a GSG linker 107 between the trimerization domain and His-tag. The furin cleavage site RRAR between Spike S1 108 and S2 is mutated to GSAS. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 138 optimal signal was observed using 1 ug/mL biotinylated ACE2-Fc protein and 6 ug/mL SA-PE The assay cutoff of 25% inhibition for the ACE2 -trimeric protein binding was 149 established based on 99th percentile cutoff using commercially available healthy normal, 150 pregnancy and potential cross reactant samples (N = 866) collected prior to November 2019. Precision was determined for low (34%), medium (65%) and high (91%) percent inhibition. Within-run, between-run, and total imprecision ranged from 0.5% to 3.9%, 1.1% to 3.4%, and 153 1.2% -7.1%, respectively. Linearity was assessed using the WHO international standard for 154 SARS-CoV-2 antibody (NIBSC code 20/136). The assay was log-log linear (r=0.99) from 80% 155 (corresponding to 1000 IU/mL) to 21% (corresponding to 31.5 IU/mL). A high sample 156 corresponding to 100% inhibition was used to demonstrate extended linearity from 80%-100%. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 184 repeated measures ANOVA, followed by the Fisher Least Significant Difference test. The 185 percent inhibition for SARS-CoV-2 variants was compared to wild-type using Deming 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 206 The performance of the plex-sVNT using wild-type trimeric spike protein was compared 207 against the PRNT virus neutralization assay for 76 samples from the COVID-19 infection cohort 208 and 102 commercially available healthy normal, pregnancy and potential cross reactant samples. The Spearman correlation between the plex-sVNT assay (cut-off, 25% inhibition) and PRNT 50 210 (cut-off, 1:10) and PRNT 90 (cut-off, 1:20) was 0.80 (95%CI: 0.69-0.88, P <0.001), and 0.88 211 (95%CI: 0.81-0.93, P<0.0001), respectively (Fig. 2, A and B) . 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 here can be adapted to monitor neutralizing antibody responses after infection and vaccination, The significance of these finding with regards to an individual's immune response is 291 currently unknown. Data on the rate of re-infection or vaccine breakthrough for these variants, 292 will be the subject of future epidemiologic research. Other mechanisms within the human 293 immune system, such as the existence of T-cell function and memory B-cells may be sufficient 294 to protect the vaccinated and those previously infected with SARS-CoV-2. A recent study 295 examined the breakthrough infection rate for individuals who received the Pfizer vaccine for 296 SARS-COV-2 variants and reported a higher incidence for the α strain after the first dose, and a 297 higher incidence for the β strain after the second dose (12). In another study, Bergwerk et al. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 298 characterized 39 healthcare workers who developed a COVID-19 infection after receiving a 299 SARS-CoV-2 vaccine. During the peri-infection period, they found lower neutralizing antibody 300 titers in blood compared with non-infected matched controls (13). They also showed that higher 301 antibody neutralizing capacity was associated with lower viral loads. The plex-sVNT would be 302 an appropriate test should evaluation of a larger population prove to be warranted for research 303 and clinical investigations. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 397 398 Table 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 425 compared to wild-type. Slope and spearman correlation is shown for each SARS-CoV-2 variant 426 compared to wild-type. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Durability of 358 mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited 362 sera Infection-and vaccine-induced antibody binding and neutralization of the B CoV-2 variant Serum 367 Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of 368 Concern in Hospitalized COVID-19 Patients Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity Methods to Study Viruses SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal 376 model Low serum 378 neutralizing anti-SARS-CoV-2 S antibody levels in mildly